SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000.
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _______________
to______________
Commission file number: 0-16159
LECTEC CORPORATION
------------------
(Exact name of Registrant as specified in its charter)
Minnesota 41-1301878
- - --------------------------------- --------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
10701 Red Circle Drive, Minnetonka, Minnesota 55343
- - --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (952) 933-2291
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
The number of shares outstanding of the registrant's common stock as of May 10,
2000 was 3,890,994 shares.
<PAGE>
LECTEC CORPORATION
FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000
TABLE OF CONTENTS
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements and Notes to Financial Statements ......... I-1
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations ............................ I-7
Item 3. Quantitative and Qualitative Disclosures About Market Risk ..... I-10
PART II - OTHER INFORMATION
Item 1. Legal Proceedings .............................................. II-1
Item 2. Changes in Securities and Use of Proceeds ...................... II-1
Item 3. Defaults Upon Senior Securities ................................ II-1
Item 4. Submission of Matters to a Vote of Security Holders ............ II-1
Item 5. Other Information .............................................. II-1
Item 6. Exhibits and Reports on Form 8-K ............................... II-1
Signature Page ................................................. II-2
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 1 - FINANCIAL STATEMENTS AND NOTES TO FINANCIAL STATEMENTS
LECTEC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
March 31, June 30,
2000 1999
------------ ------------
(Unaudited)
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 35,910 $ 1,022,025
Receivables
Trade, net of allowances of $116,921 (unaudited) and $101,751
at March 31, 2000 and June 30, 1999 2,537,196 2,335,314
Refundable income taxes -- 7,544
Other 3,716 8,687
------------ ------------
2,540,912 2,351,545
Inventories
Raw materials 1,635,357 1,324,973
Work-in-process 46 69,324
Finished goods 712,134 602,227
------------ ------------
Total inventories 2,347,537 1,996,524
Prepaid expenses and other 233,644 174,674
Deferred income taxes 354,000 354,000
------------ ------------
Total current assets 5,512,003 5,898,768
PROPERTY, PLANT AND EQUIPMENT - AT COST
Land 247,731 247,731
Building and improvements 1,938,996 1,841,742
Equipment 7,382,996 7,157,016
Furniture and fixtures 413,013 413,013
------------ ------------
9,982,736 9,659,502
Less accumulated depreciation 6,232,544 5,631,011
------------ ------------
3,750,192 4,028,491
OTHER ASSETS
Patents and trademarks, less accumulated amortization of $1,258,829
(unaudited) and $1,154,698 at March 31, 2000 and June 30, 1999 168,787 199,971
Other 5,343 5,343
------------ ------------
174,130 205,314
------------ ------------
$ 9,436,325 $ 10,132,573
============ ============
</TABLE>
See accompanying notes to the consolidated financial statements.
I-1
<PAGE>
LECTEC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS - CONTINUED
<TABLE>
<CAPTION>
March 31, June 30,
2000 1999
------------ ------------
(Unaudited)
<S> <C> <C>
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Line of credit $ 412,418 $ --
Accounts payable 2,223,804 1,676,776
Accrued expenses
Payroll related 493,436 403,075
Retail support programs 431,756 165,472
Other 184,353 181,730
------------ ------------
Total current liabilities 3,745,767 2,427,053
DEFERRED INCOME TAXES 197,000 197,000
SHAREHOLDERS' EQUITY
Common stock, $.01 par value: 15,000,000 shares authorized;
3,890,494 shares (unaudited) and 3,876,476 shares issued
and outstanding at March 31, 2000 and June 30, 1999 38,905 38,765
Additional paid-in capital 11,289,329 11,262,654
Accumulated other comprehensive loss (11,841) (11,841)
Deficit in retained earnings (5,822,835) (3,781,058)
------------ ------------
5,493,558 7,508,520
------------ ------------
$ 9,436,325 $ 10,132,573
============ ============
</TABLE>
See accompanying notes to the consolidated financial statements.
I-2
<PAGE>
LECTEC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Three months ended Nine months ended
March 31, March 31,
----------------------------- -----------------------------
2000 1999 2000 1999
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
Net sales $ 3,934,825 $ 3,196,311 $ 10,243,282 $ 9,202,645
Cost of goods sold 2,423,164 2,027,130 6,729,326 6,090,473
------------ ------------ ------------ ------------
Gross profit 1,511,661 1,169,181 3,513,956 3,112,172
Operating expenses
Sales and marketing 1,240,070 651,926 2,838,770 1,531,397
General and administrative 643,948 586,442 1,891,821 1,954,533
Research and development 264,896 298,367 844,860 864,405
------------ ------------ ------------ ------------
2,148,914 1,536,735 5,575,451 4,350,335
------------ ------------ ------------ ------------
Loss from operations (637,253) (367,554) (2,061,495) (1,238,163)
Other income (expense), net (6,075) 19,788 19,718 78,576
------------ ------------ ------------ ------------
Loss before income taxes (643,328) (347,766) (2,041,777) (1,159,587)
Income tax expense -- 1,103 -- 2,715
------------ ------------ ------------ ------------
Net loss $ (643,328) $ (348,869) $ (2,041,777) $ (1,162,302)
============ ============ ============ ============
Net loss per share - basic and diluted $ (0.17) $ (0.09) $ (0.53) $ (0.30)
============ ============ ============ ============
Weighted average shares outstanding - basic and diluted 3,890,494 3,867,774 3,882,746 3,920,037
============ ============ ============ ============
</TABLE>
See accompanying notes to the consolidated financial statements.
I-3
<PAGE>
LECTEC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
Nine Months Ended March 31,
-----------------------------
2000 1999
------------ ------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (2,041,777) $ (1,162,302)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 707,403 634,554
Gain on sale of equipment (166) --
Changes in operating assets and liabilities:
Trade and other receivables (189,367) (436,801)
Refundable income taxes -- 52,000
Inventories (351,013) (174,800)
Prepaid expenses and other (58,970) (89,893)
Accounts payable 455,574 605,415
Accrued expenses 359,268 119,377
------------ ------------
Net cash used in operating activities (1,119,048) (452,450)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment (326,215) (254,928)
Investment in patents and trademarks (72,947) (68,258)
Proceeds from sale of equipment 1,408 --
------------ ------------
Net cash used in investing activities (397,754) (323,186)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net borrowings on line of credit 412,418 --
Issuance of common stock 26,815 --
Repurchases and retirement of common stock -- (543,399)
Cash overdraft 91,454 --
------------ ------------
Net cash provided by (used) in financing activities 530,687 (543,399)
------------ ------------
Net decrease in cash and cash equivalents (986,115) (1,319,035)
Cash and cash equivalents at beginning of period 1,022,025 2,186,532
------------ ------------
Cash and cash equivalents at end of period $ 35,910 $ 867,497
============ ============
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest expense $ 5,233 $ --
Income taxes -- 22,128
</TABLE>
See accompanying notes to the consolidated financial statements.
I-4
<PAGE>
LECTEC CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
QUARTERS ENDED MARCH 31, 2000 AND 1999
(UNAUDITED)
(1) GENERAL
The accompanying consolidated financial statements include the accounts
of LecTec Corporation (the "Company") and LecTec International Corporation, a
wholly-owned subsidiary which was dissolved and merged into LecTec Corporation
on December 31, 1999. All significant intercompany balances and transactions
have been eliminated in consolidation. The Company's financial statements for
the three months and nine months ended March 31, 2000 should be read in
conjunction with its Annual Report on Form 10-K and its Annual Report to
Shareholders for the fiscal year ended June 30, 1999. The interim financial
statements are unaudited and in the opinion of management, reflect all
adjustments necessary for a fair presentation of results for the periods
presented. Results for interim periods are not necessarily indicative of results
for the year.
(2) NET LOSS
The Company's basic net loss per share amounts have been computed by
dividing net loss by the weighted average number of outstanding common shares.
The Company's diluted net loss per share amounts have been computed by dividing
net loss by the weighted average number of outstanding common shares and common
share equivalents, when dilutive. Options and warrants to purchase 976,705 and
888,822 shares of common stock with a weighted average exercise price of $5.83
and $7.56 were outstanding during the three months ended March 31, 2000 and
1999, but were excluded because they were antidilutive. Options and warrants to
purchase 1,054,530 and 876,489 shares of common stock with a weighted average
exercise price of $6.19 and $7.64 were outstanding during the nine months ended
March 31, 2000 and 1999, but were excluded because they were antidilutive.
(3) COMPREHENSIVE LOSS
For the quarter and nine months ended March 31, 2000 and 1999, there
were no items which the Company is required to recognize as components of
comprehensive income (loss), therefore comprehensive loss was the same as net
loss.
(4) SEGMENTS
The Company operates its business in one reportable segment - the
manufacture and sale of products based on advanced skin interface technologies.
Each of the Company's major product lines has similar economic characteristics,
technology, manufacturing processes, and regulatory environments. Customers and
distribution and marketing strategies vary within major product lines as well as
overlap between major product lines. The Company's executive decision makers
evaluate sales performance based on the total sales of each major product line
and profitability on a total company basis, due to shared infrastructures, to
make operating and strategic decisions. Net sales by major product line were as
follows:
Three months ended March 31, 2000 1999
------ ------
Conductive products $1,988,864 $1,928,691
Medical tape products 525,149 701,701
Therapeutic consumer products 1,420,812 565,919
--------- ---------
$3,934,825 $3,196,311
========= =========
I-5
<PAGE>
Nine months ended March 31, 2000 1999
------ ------
Conductive products $5,493,225 $5,858,262
Medical tape products 1,546,511 2,168,121
Therapeutic consumer products 3,203,546 1,176,262
--------- ---------
$10,243,282 $9,202,645
========== =========
(5) LINE OF CREDIT AND LIQUIDITY
In November 1999, the Company finalized a $2,000,000 line of credit
which expires in November 2001. The line of credit is secured by the Company's
receivables, inventory and equipment, and bears interest at the lending bank's
prime rate plus three percentage points. Borrowings outstanding on the line of
credit as of March 31, 2000, were $412,418. The credit agreement contains
certain restrictive covenants which require the Company to maintain, among other
things, specified levels of net worth and not to exceed specified cumulative
losses. The Company was in compliance with all covenants as of March 31, 2000.
The Company had negative cash flows from operations of $1,119,048 for
the nine months ended March 31, 2000. This cash requirement was satisfied
principally from existing cash balances and the line of credit. Management is
evaluating additional sources of capital that will be required to meet future
operating cash flow requirements and the longer term expansion of the business.
(6) STOCK REPURCHASE PROGRAM
In April 1998, the Company's Board of Directors authorized a stock
repurchase program pursuant to which up to 500,000 shares, or approximately
12.9% of the Company's outstanding common stock, may be repurchased. The shares
may be purchased from time to time through open market transactions, block
purchases, tender offers, or in privately negotiated transactions. The total
consideration for all shares repurchased under this program cannot exceed
$2,000,000. During the quarter ended March 31, 2000 no shares were repurchased
and during the quarter ended March 31, 1999, 10,000 shares were repurchased for
$19,062. During the nine months ended March 31, 2000 no shares were repurchased
and during the nine months ended March 31, 1999, 175,650 shares were repurchased
for $543,399. Through March 31, 2000 the Company has repurchased a total of
205,150 shares at a cost of $667,962 under this program.
(7) EMPLOYEE STOCK PURCHASE PLAN
The Company's employee stock purchase plan, adopted November 19, 1998,
allows eligible employees to purchase shares of the Company's common stock
through payroll deductions. The purchase price is the lower of 85% of the fair
market value of the stock on the first or last day of each six-month period
during which an employee participated in the plan. The Company has reserved
200,000 shares under the plan of which 14,018 shares were purchased by employees
for $26,815 during the first nine months of fiscal 2000. As of March 31, 2000
employees have purchased a total of 29,144 shares for $59,821.
I-6
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
QUARTERS AND NINE MONTHS ENDED MARCH 31, 2000 AND 1999
RESULTS OF OPERATIONS
Net sales for the third quarter of fiscal 2000 were $3,934,825 compared
to net sales of $3,196,311 for the third quarter of fiscal 1999, an increase of
23.1%. The increase was primarily the result of increased therapeutic consumer
product sales which more than offset decreased medical tape sales. Therapeutic
consumer product sales increased by 151.1% from $565,919 to $1,420,812 while
conductive product sales, the Company's largest product group, increased by 3.1%
and medical tape product sales decreased by 25.2%. The therapeutic consumer
product sales increase was primarily the result of initial sales of a new acne
product to Neutrogena Corporation as well as increased TheraPatch(R) sales
volume, especially TheraPatch Vapor products. The decrease in medical tape
product sales was primarily due to the absence of sales to a former low-margin
slit roll tape customer.
Net sales for the first nine months of fiscal 2000 were $10,243,282
compared to net sales of $9,202,645 for the first nine months of fiscal 1999, an
increase of 11.3%. The increase was primarily the result of increased
therapeutic consumer product sales which more than offset decreased medical tape
and conductive product sales. Therapeutic consumer product sales increased by
172.4% from $1,176,262 to $3,203,546 while conductive product sales, the
Company's largest product group, decreased by 6.2% and medical tape product
sales decreased by 28.7%. The therapeutic consumer product sales increase was
primarily the result of increased TheraPatch sales volume, especially TheraPatch
Vapor products and initial sales of the new acne product to Neutrogena
Corporation. The conductive product sales decrease was primarily the result of
the absence of sales to a former customer who began manufacturing their own
product in the fourth quarter of fiscal 1999. Sales to the former customer in
the first nine months of fiscal 1999 were approximately $485,000. Medical tape
product sales decreased primarily due to reduced sales to a low-margin slit roll
tape customer and decreases in sales volume to several other low-margin medical
tape customers.
Gross profit for the third quarter of fiscal 2000 was $1,511,661
compared to $1,169,181 for the third quarter of fiscal 1999, an increase of
29.3%. Gross profit as a percent of net sales for the third quarter of fiscal
2000 was 38.4% compared to 36.6% for the third quarter of fiscal 1999. The
increase in gross profit for the quarter resulted primarily from increased sales
volume and the favorable impact of a change in the sales mix toward
higher-margin therapeutic consumer products which more than offset increased
labor costs. Labor costs were higher in the current quarter primarily due to an
increase in staffing levels and overtime related to the production of
therapeutic patch products.
Gross profit for the first nine months of fiscal 2000 was $3,513,956
compared to $3,112,172 for the first nine months of fiscal 1999, an increase of
12.9%. Gross profit as a percent of net sales for the first nine months of
fiscal 2000 was 34.3% compared to 33.8% for the first nine months of fiscal
1999. The increase in gross profit for the nine months resulted primarily from
increases sales volume and the favorable impact of a change in the sales mix
toward higher-margin therapeutic consumer products which more than offset
increased labor costs and depreciation expense. Labor costs were higher in the
current nine months primarily due to an increase in staffing levels and overtime
related to the production of therapeutic consumer patch products.
Sales and marketing expenses were $1,240,070 and $651,926 during the
third quarters of fiscal 2000 and 1999, and as a percentage of net sales, were
31.5% and 20.4%. The increase in sales and marketing expenses for the quarter
was primarily due to increased media advertising expenses, retail slotting fees
and cooperative expenses related to sales of the TheraPatch product line. The
Company anticipates that sales and marketing expenses as a percent of sales for
the fourth quarter of fiscal 2000
I-7
<PAGE>
will be comparable to the third quarter of fiscal 2000 due to marketing programs
associated with the TheraPatch product line.
Sales and marketing expenses were $2,838,770 and $1,531,397 during the
first nine months of fiscal 2000 and 1999, and as a percentage of net sales,
were 27.7% and 16.6%. The increase in sales and marketing expenses for the first
nine months was primarily due to increased retail slotting fees and advertising
and cooperative expenses related to the TheraPatch product line.
General and administrative expenses were $643,948 and $586,442 during
the third quarters of fiscal 2000 and 1999, and as a percentage of net sales,
were 16.4% and 18.4%. The increase in general and administrative expenses for
the quarter was primarily due to increased consulting expenses.
General and administrative expenses were $1,891,821 and $1,954,533
during the first nine months of fiscal 2000 and 1999, and as a percentage of net
sales, were 18.5% and 21.2%. The decrease in general and administrative expenses
for the first nine months of fiscal 2000 was primarily due to decreased legal
expenses. Legal expenses in the prior year included approximately $126,000 of
expenses associated with the renegotiation and modification of the license
agreement for the development and commercialization of cotinine.
Research and development expenses for the third quarters of fiscal 2000
and 1999 were $264,896 and $298,367, and as a percentage of net sales, were 6.7%
and 9.3%. The decrease in research and development expense for the current
quarter primarily reflects decreased test-run production costs and supplies.
Research and development expenses for the first nine months of fiscal
2000 and 1999 were $884,860 and $864,405, and as a percentage of net sales, were
8.3% and 9.4%. The decrease in research and development expense for the first
nine months of fiscal 2000 primarily reflects increased labor costs which were
more than offset by a decrease in test-run production costs and supplies.
Other income (expense), net, decreased in the third quarter of fiscal
2000 to net expense of $6,075 from net income of $19,788 in the third quarter of
fiscal 1999. Other income, net, decreased in the first nine months of fiscal
2000 to $19,718 from $78,576 in the first nine months of fiscal 1999. Both of
the fiscal 2000 decreases were primarily the result of decreased interest income
due to lower cash and cash equivalent balances and higher interest expense in
the third quarter of fiscal 2000 related to the line of credit.
The Company recorded a loss before income taxes of $643,328 in the
third quarter of fiscal 2000 compared to a loss before income taxes of $347,766
for the third quarter of fiscal 1999. The Company recorded a loss before income
taxes of $2,041,777 in the first nine months of fiscal 2000 compared to a loss
before income taxes of $1,159,587 for the first nine months of fiscal 1999. The
increased loss in the current year third quarter and first nine months was
primarily the result of increased sales and marketing expenses related to retail
sales of the Company's TheraPatch products. The increased sales and marketing
expenses more than offset an increase in gross profit that resulted from
increased sales volume and a shift in the sales mix toward higher-margin
therapeutic consumer products. The Company expects to incur similar losses in
the fourth quarter of fiscal 2000 as it continues to incur increased sales and
marketing expenses related to retail sales of TheraPatch consumer products.
The Company recorded no income tax expense or benefit in the third
quarter and first nine months of fiscal 2000 compared to nominal income tax
expense in the third quarter and first nine months of the prior year. There was
no income tax benefit recorded during the third quarter and first nine months of
fiscal 2000 since the loss benefit may not be realizable by the Company. Income
tax expense in the third quarter and first nine months of fiscal 1999 reflects
minimal tax expense associated with the Company's foreign sales corporation
subsidiary.
Inflation has not had a significant impact on the Company's operations
or cash flow.
I-8
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents decreased by $986,115 to $35,910 during the
first nine months of fiscal 2000. Accounts receivable increased by $189,367 to
$2,540,912 primarily due to increased sales for March 2000 as compared to June
1999. Inventories increased by $351,013 to $2,347,537 primarily due to increased
raw materials and finished goods inventory related to therapeutic products which
was partially offset by decreased finished goods inventory of medical tape.
Accounts payable of $2,223,804 at March 31, 2000 increased by $547,028 during
the first nine months primarily due to increased payables related to increased
manufacturing production. Capital spending for manufacturing equipment and plant
improvements totaled $326,215 during the first nine months of fiscal 2000. There
were no material commitments for capital expenditures at March 31, 2000.
The Company had working capital of $1,766,236 and a current ratio of
1.5 at March 31, 2000 compared to working capital of $3,471,715 and a current
ratio of 2.4 at June 30, 1999.
There was no long-term debt outstanding at March 31, 2000 or June 30,
1999. The Company finalized a $2,000,000 asset-based line of credit in November,
1999 and borrowings outstanding on the line of credit were $412,418 as of March
31, 2000. The Company was in compliance with all covenants as of March 31, 2000.
Management believes that internally-generated cash flow and the secured
line of credit will be sufficient to support anticipated operating requirements
through the fourth quarter of the current fiscal year that will end June 30,
2000. Management expects additional sources of cash in the next six months to
include the proceeds from a mortgage or a sale and leaseback transaction of its
corporate facility in Minnetonka, Minnesota, along with equipment financing to
fund planned capital expenditures in the next six to twelve months. Additional
sources of capital that will be required to enable the Company to meet its
obligations, operating cash flow requirements and to support the longer term
growth and expansion of the business are currently being evaluated by
management. Maintaining adequate levels of working capital depends in part upon
the success of the Company's products in the marketplace, the relative
profitability of those products and the Company's ability to control operating
expenses. Funding of the Company's operations in future periods is expected to
require additional investments in the Company in the form of equity or debt.
There can be no assurance that the Company will achieve desired levels of sales
or profitability, or that future capital infusions will be available.
FORWARD-LOOKING STATEMENTS
From time to time, in reports filed with the Securities and Exchange
Commission (including this Form 10-Q), in press releases, and in other
communications to shareholders or the investment community, the Company may
provide forward-looking statements concerning possible or anticipated future
results of operations or business developments which are typically preceded by
the words "believes", "expects", "anticipates", "intends", "will", "may",
"should" or similar expressions. Such forward-looking statements are subject to
risks and uncertainties which could cause results or developments to differ
materially from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the buying patterns of major
customers; competitive forces including new products or pricing pressures; costs
associated with and acceptance of the Company's TheraPatch brand strategy;
impact of interruptions to production; dependence on key personnel; need for
regulatory approvals; changes in governmental regulatory requirements or
accounting pronouncements; and ability to satisfy funding requirements for
operating needs, expansion or capital expenditures.
I-9
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company has no history of, and does not anticipate in the future,
investing in derivative financial instruments, derivative commodity instruments
or other such financial instruments. Transactions with international customers
are entered into in U.S. dollars, precluding the need for foreign currency
hedges. Additionally, the Company invests in money market funds and short-term
commercial paper, which experience minimal volatility. Thus, the exposure to
market risk is not material.
I-10
<PAGE>
PART II
OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
None.
Item 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
Not applicable.
Item 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
Item 5. OTHER INFORMATION
None.
Item 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) EXHIBITS
Item No. Item Method of Filing
-------- ---------------- ----------------
27 Financial data schedule Filed herewith
(b) REPORTS ON FORM 8-K
None.
II-1
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
LECTEC CORPORATION
Date May 11, 2000 /s/ Rodney A. Young
---------------- ----------------------------------------------------
Rodney A. Young, Chief Executive Officer & President
Date May 11, 2000 /s/ Deborah L. Moore
---------------- ----------------------------------------------------
Deborah L. Moore, Chief Financial Officer
II-2
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUN-30-2000
<PERIOD-END> MAR-31-2000
<CASH> 35,910
<SECURITIES> 0
<RECEIVABLES> 2,657,833
<ALLOWANCES> 116,921
<INVENTORY> 2,347,537
<CURRENT-ASSETS> 5,512,003
<PP&E> 9,982,736
<DEPRECIATION> 6,232,544
<TOTAL-ASSETS> 9,436,325
<CURRENT-LIABILITIES> 3,745,767
<BONDS> 0
0
0
<COMMON> 38,905
<OTHER-SE> 5,454,653
<TOTAL-LIABILITY-AND-EQUITY> 9,436,325
<SALES> 10,243,282
<TOTAL-REVENUES> 10,243,282
<CGS> 6,729,326
<TOTAL-COSTS> 12,304,777
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 36,000
<INTEREST-EXPENSE> 8,808
<INCOME-PRETAX> (2,041,777)
<INCOME-TAX> 0
<INCOME-CONTINUING> (2,041,777)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,041,777)
<EPS-BASIC> (0.53)
<EPS-DILUTED> (0.53)
</TABLE>
